TRM1 Antibody

What is TRM1/TRMT1 and why is it significant in research?

TRM1 (also known as TRMT1) is a tRNA methyltransferase that dimethylates a single guanine residue at position 26 of most tRNAs using S-adenosyl-L-methionine as the methyl donor . This modification protects tRNA structure, facilitates proper folding, and enhances interaction with ribosomal components . TRMT1 is significant in research because it impacts global protein translation levels, including proteins involved in cellular growth, development, and stress response . Research has shown that TRMT1-deficient cells exhibit hypersensitivity to redox stress, indicating its importance in maintaining cellular homeostasis .

What types of TRM1/TRMT1 antibodies are available for research applications?

Several types of TRM1/TRMT1 antibodies are available for research, including:

These antibodies target different regions of TRMT1, with some recognizing specific domains (methyltransferase domain, zinc finger domain) or particular epitopes within the protein .

How do I select the appropriate TRM1/TRMT1 antibody for my research?

When selecting a TRM1/TRMT1 antibody, consider these factors:

• Target species: Ensure the antibody has been validated for your species of interest (human, mouse, rat)

• Application: Verify the antibody has been validated for your specific application (WB, IP, IHC, IF/ICC)

• Domain specificity: Some antibodies recognize specific domains of TRMT1:

  • Dual-domain recognizing antibodies (targeting both methyltransferase and zinc finger domains)

  • Single-domain recognizing antibodies (targeting only the zinc finger domain)

• Epitope location: Consider whether the epitope is in a region susceptible to proteolytic cleavage, which is important in SARS-CoV-2 research where Mpro cleavage occurs between the methyltransferase and zinc finger domains

• Validation data: Review the manufacturer's validation data for specificity and sensitivity

What are the optimal conditions for Western blotting with TRM1/TRMT1 antibodies?

For optimal Western blotting with TRM1/TRMT1 antibodies:

• Sample preparation: Use whole cell lysates from HeLa, HEK293T, or similar cell lines

• Loading amount: 20-40 μg of total protein is typically sufficient

• Antibody dilution: Use recommended dilutions:

  • ab283652: 1/1000

  • 14970-1-AP: 1/600-1/3000

  • TA382848: 1/500-1/2000

• Predicted molecular weight: TRMT1 appears at approximately 72-75 kDa

• Blocking buffer: 5% non-fat dry milk in TBST or Intercept® (TBS) Blocking Buffer

• Detection method: HRP-conjugated secondary antibodies with chemiluminescence detection; exposure times of 48 seconds to 3 minutes have been validated

• Note on non-specific bands: Be aware that non-specific bands at approximately 100 kDa and 17 kDa may appear with some antibodies

How can I validate TRMT1 antibody specificity in my experimental system?

To validate TRMT1 antibody specificity:

• siRNA knockdown: Use TRMT1-targeted siRNAs to demonstrate reduced signal intensity compared to scrambled siRNA controls

• Knockout/null controls: Compare antibody reactivity in TRMT1 wildtype versus knockout cells

• Overexpression: Compare endogenous TRMT1 signals with overexpressed TRMT1-tagged constructs (e.g., TRMT1-FLAG)

• Multiple antibodies: Use antibodies targeting different epitopes of TRMT1 to confirm consistent results

• Peptide competition: Pre-incubate antibody with immunizing peptide to demonstrate signal reduction

• Molecular weight verification: Confirm that the observed band corresponds to the predicted molecular weight (72 kDa)

• Proteolytic cleavage: In studies involving SARS-CoV-2 Mpro, verify that cleavage produces the expected fragment patterns when using domain-specific antibodies

What are the recommended protocols for immunoprecipitation using TRM1/TRMT1 antibodies?

For immunoprecipitation with TRM1/TRMT1 antibodies:

• Antibody selection: Use antibodies validated for IP, such as ab186019

• Antibody amount: Use approximately 6 μg antibody per mg of cell lysate

• Lysate preparation: Use 1 mg of total protein lysate for IP

• Loading for detection: Load approximately 20% of the IP sample for Western blot analysis

• Controls: Include:

  • IgG control to detect non-specific binding

  • Input sample (typically 5-10% of starting material)

  • IP with catalytically inactive protein partners (e.g., Mpro Cys145Ala) as a binding control in interaction studies

• Detection: Use anti-TRMT1 antibodies with appropriate dilutions for Western blot detection of IP samples

How can I use TRMT1 antibodies to study its cleavage by SARS-CoV-2 Mpro?

To study TRMT1 cleavage by SARS-CoV-2 Mpro:

• Dual antibody approach: Use two TRMT1-specific antibodies:

  • A dual-domain recognizing antibody (e.g., anti-TRMT1 460-659)

  • A single-domain recognizing antibody (e.g., anti-TRMT1 609-659)

• Experimental setup:

  • Incubate purified TRMT1 with active Mpro (WT) or catalytically inactive Mpro (Cys145Ala)

  • Monitor TRMT1 cleavage by Western blot using both antibodies

  • Full-length TRMT1 (~72 kDa) will be detected by both antibodies

  • After cleavage, separate fragments will be detected by specific antibodies:

    • Zinc finger domain fragment: detectable by both antibodies

    • Methyltransferase domain fragment: detectable only by the dual-domain antibody

• Validation in cell lysates:

  • Incubate human cell lysates (e.g., HEK293T) with active or inactive Mpro

  • Use GAPDH as a loading control

  • Monitor endogenous TRMT1 cleavage over time (e.g., 2-hour time course)

• Functional assessment:

  • Compare tRNA methyltransferase activity of cleaved versus intact TRMT1 using radiolabeled S-adenosyl methionine (14C-SAM)

  • Measure tRNA binding affinity using electrophoretic mobility shift assays (EMSAs)

How can TRMT1 antibodies be used to study the impact of TRMT1 on tRNA modification and cellular function?

To study TRMT1's impact on tRNA modification and cellular function:

• TRMT1 knockdown/knockout validation:

  • Validate TRMT1 depletion by Western blot with TRMT1 antibodies

  • Use multiple antibodies to confirm complete protein loss

• tRNA modification analysis:

  • Isolate total tRNA from control and TRMT1-depleted cells

  • Use Northern blotting with specific probes for G26-containing tRNAs

  • Alternatively, employ tRNA sequencing approaches to identify all TRMT1 targets

• Cellular function studies:

  • Examine cellular responses to oxidative stress in TRMT1-depleted versus control cells

  • Monitor global protein translation levels

  • Investigate impact on specific tRNA species stability and function

• TRMT1 variant studies:

  • Use Western blotting to validate expression of TRMT1 variants

  • Immunofluorescence to examine subcellular localization changes

  • Co-immunoprecipitation to detect altered protein interactions

• TRMT1 vs. TRMT1L comparison:

  • Use specific antibodies to distinguish between TRMT1 and its paralog TRMT1L

  • Compare tRNA modification profiles when either enzyme is depleted

What experimental controls should be included when using TRMT1 antibodies for interaction studies?

When studying TRMT1 interactions:

• Antibody controls:

  • IgG isotype control for non-specific binding

  • Pre-immune serum (for polyclonal antibodies)

  • Antibody pre-absorbed with immunizing peptide

• Protein expression controls:

  • siRNA/shRNA knockdown for specificity validation

  • Multiple antibodies targeting different TRMT1 epitopes

• Interaction-specific controls:

  • Catalytically inactive mutants (e.g., Mpro Cys145Ala)

  • Domain deletion mutants

  • Point mutants at key interaction interfaces

  • Competition with purified domains or peptides

• Reciprocal co-IP:

  • IP with anti-TRMT1 and blot for partner protein

  • IP with antibody against partner protein and blot for TRMT1

• Cellular context controls:

  • Cell type-specific differences

  • Stress condition variations (e.g., oxidative stress)

  • Viral infection time course (for viral protein interactions)

How do I distinguish between specific and non-specific bands when using TRM1/TRMT1 antibodies?

To distinguish between specific and non-specific bands:

• Expected molecular weight: The specific TRMT1 band should appear at approximately 72-75 kDa

• Known non-specific bands:

  • Some antibodies show non-specific bands at approximately 100 kDa and 17 kDa

  • A non-specific band at 65 kDa has been reported with some antibodies

• Validation approaches:

  • siRNA knockdown: Specific bands should decrease in intensity

  • Multiple antibodies: Specific bands should be detected by antibodies targeting different epitopes

  • Peptide competition: Pre-incubation with immunizing peptide should eliminate specific bands

  • Overexpression: TRMT1-FLAG or other tagged constructs show increased intensity of specific bands

• Cleaved fragments:

  • When studying SARS-CoV-2 Mpro cleavage, distinguish between full-length TRMT1 and cleaved fragments

  • Use domain-specific antibodies to identify specific fragments

What are common challenges in working with TRM1/TRMT1 antibodies and how can they be addressed?

How can I interpret changes in TRM1/TRMT1 levels during SARS-CoV-2 infection?

When interpreting changes in TRMT1 levels during SARS-CoV-2 infection:

• Expected changes:

  • SARS-CoV-2 infection can reduce TRMT1 levels by approximately 30% at 24-48 hours post-infection

  • Mpro cleaves TRMT1 between the methyltransferase and zinc finger domains (at position ~530)

• Detection methods:

  • Use domain-specific antibodies to monitor full-length TRMT1 and cleaved fragments

  • The dual-domain antibody (anti-TRMT1 460-659) will detect both fragments

  • The zinc finger domain-specific antibody (anti-TRMT1 609-659) will only detect the C-terminal fragment

• Functional consequences:

  • Cleaved TRMT1 shows reduced tRNA binding affinity (~6-fold decrease)

  • Complete loss of tRNA methyltransferase activity

  • Potential formation of oligomeric complexes with altered migration patterns

• Biological significance:

  • Disruption of TRMT1-mediated tRNA modification impacts global translation

  • May contribute to cellular stress responses during infection

  • Potential link to neurological and redox-related COVID-19 phenotypes

• Controls and validation:

  • Compare with other viral proteases or stressors

  • Use catalytically inactive Mpro (Cys145Ala) as a binding control

  • Monitor tRNA modification levels using appropriate assays

How can TRM1/TRMT1 antibodies be used to study the differential roles of TRMT1 and TRMT1L in tRNA modification?

Recent research has identified distinct roles for TRMT1 and its paralog TRMT1L in tRNA modification . To study their differential roles:

• Antibody selection:

  • Use antibodies specific for either TRMT1 or TRMT1L

  • Validate specificity using knockdown/knockout systems

• Comparative analysis:

  • TRMT1 methylates tRNAs with guanosine at position 26

  • TRMT1L methylates guanosine at position 27 specifically in tyrosine tRNAs

  • TRMT1L is also necessary for maintaining acp3U modifications in a subset of tRNAs

• Experimental approaches:

  • Immunoprecipitation to identify specific protein complexes

  • ChIP-seq or CLIP-seq to identify binding sites on tRNAs

  • Co-localization studies using immunofluorescence

  • Comparative analysis of tRNA stability and function in cells depleted of either enzyme

• Disease relevance:

  • Evaluate TRMT1 and TRMT1L levels in patient cells with disease-associated variants

  • Monitor tyrosine and serine tRNA levels, which are particularly dependent on m2,2G modifications

What are the considerations for using TRM1/TRMT1 antibodies in studying neurological disorders?

TRMT1 deficiency has been linked to neurological dysfunction . When using TRMT1 antibodies in neurological research:

• Tissue-specific considerations:

  • Validate antibody performance in neural tissues

  • Optimize protocols for brain tissue lysates or sections

  • Consider species differences in TRMT1 sequence and expression

• Patient sample analysis:

  • Compare TRMT1 levels and localization in patient versus control samples

  • Correlate with clinical phenotypes

  • Monitor tRNA modification levels in parallel

• Experimental models:

  • Validate TRMT1 knockdown efficiency in neuronal cell models

  • Use immunostaining to examine TRMT1 localization changes under stress conditions

  • Study interaction with other neurologically relevant proteins

• Technical considerations:

  • Use fixation methods compatible with neuronal tissue

  • Optimize antigen retrieval for immunohistochemistry

  • Consider background autofluorescence in brain tissue

How can TRM1/TRMT1 antibodies be integrated into multi-omics approaches to study tRNA biology?

To integrate TRMT1 antibodies into multi-omics approaches:

• Immunoprecipitation followed by sequencing (IP-seq):

  • Use TRMT1 antibodies to immunoprecipitate TRMT1-bound tRNAs

  • Sequence associated tRNAs to identify all targets

  • Compare with tRNA sequencing results from TRMT1-depleted cells

• Proteomics integration:

  • Use TRMT1 antibodies for co-immunoprecipitation followed by mass spectrometry

  • Identify TRMT1 interaction partners under different conditions

  • Correlate with changes in the translational landscape

• Spatial analysis:

  • Combine immunofluorescence with RNA FISH to correlate TRMT1 localization with tRNA distribution

  • Perform proximity ligation assays to detect interactions with translation machinery components

• Functional genomics:

  • Use TRMT1 antibodies to validate CRISPR screen hits related to tRNA modification

  • Correlate protein expression changes with alterations in tRNA modifications and translational efficiency

• Temporal dynamics:

  • Track TRMT1 localization and modification activity during cellular stress responses

  • Correlate with changes in translational programs and cellular phenotypes